Sage Journals: Discover world-class research

Abstract

We sought to investigate whether the Montreal Cognitive Assessment (MoCA) could provide a brief assessment of recall and recognition using Huntington disease (HD) and Alzheimer disease (AD) as disorders characterized by different memory deficits. This study included 80 participants with HD, 64 participants with AD, and 183 community-dwelling control participants. Random-effects hierarchical logistic regressions were performed to assess the relative performance of the normal control (NC), participants with HD, and participants with AD on verbal free recall, cued recall, and multiple-choice recognition on the MoCA. The NC participants performed significantly better than participants with AD at all the 3 levels of assessment. No difference existed between participants with HD and NC for cued recall, but NC participants performed significantly better than participants with HD on free recall and recognition. The participants with HD performed significantly better than participants with AD at all the 3 levels of assessment. The MoCA appears to be a valuable, brief cognitive assessment capable of identifying specific memory deficits consistent with known differences in memory profiles.

Keywords

Huntington disease Alzheimer disease Montreal Cognitive Assessment (MoCA)recall recognition

Memory is a complex, multidimensional construct. In order to parse it into more concrete components, neuropsychologists often refer to memory with respect to particular, constituent cognitive processes (eg, encoding vs retrieval) or the informational content to be recalled (eg, semantic vs episodic). Unfortunately, its multidimensional nature presents challenges for assessment, especially in clinical and clinical trial settings where time constraints are limiting. Brief measures that examine multiple dimensions of memory functioning are needed to facilitate assessment of patients with different forms of dementia.

Many disorders (eg, Alzheimer disease [AD], mild cognitive impairment [MCI]) have historically been characterized and diagnosed solely by changes in cognition, including memory. Other disorders, such as diseases affecting the basal ganglia (eg, Huntington disease [HD], Parkinson disease [PD]), have also been shown to produce significant changes in memory.^1
-3 For instance, in HD, overall memory, as well as visual, verbal, and episodic memory, have been shown to decline over the course of disease progression.^4

-7 Over the past few decades, the interest in and recognized importance of assessing memory in diseases such as HD and PD have increased immensely. Unfortunately, the challenge of assessing memory briefly now pervades the evaluation of these disorders as well, and many assessments of memory profiles are time consuming and difficult to administer for examiners and to complete for patients. In order to increase clinicians’ and researchers’ abilities to examine specific memory profiles, brief yet sensitive measures are needed—the Montreal Cognitive Assessment (MoCA) may be such a measure. The purpose of this study is to investigate whether the MoCA could provide a brief assessment of unique recall and recognition issues found in patients with HD and AD.

The MoCA is a relatively new, brief cognitive assessment. It was developed by Nasreddine et al as a screening measure to assess the more subtle deteriorations of memory that occur in MCI.⁸ Research exploring the utility of the MoCA suggests it may have sensitivity and specificity superior to other commonly used brief cognitive assessments (eg, the Mini-Mental State Examination [MMSE]) for a variety of dementing disorders and general cognitive deficits.^2,8

-14 Researchers have demonstrated that the MoCA is effective in identifying cognitive impairment among patients with PD and HD.^15
-17 Specifically, among patients with HD, the MoCA has been shown to have high specificity and sensitivity in detecting cognitive dysfunction.¹⁶ It has also been studied for its utility in assessing cognitive functioning among patients with AD. Cecato et al compared the total MoCA score and subtest scores among healthy control, participants with MCI, and participants with mild AD.¹⁸ They showed that the MoCA total score effectively discriminated between the groups and that clock drawing, rhino naming, word recall, and orientation subtests differentiated between those with AD and MCI. Costa et al further demonstrated that the MoCA effectively detects changes in cognitive functioning over time among patients with AD.¹⁹ In addition, Julayanont et al demonstrated the utility of the MoCA in predicting the risk of conversion from MCI to AD.²⁰ These findings suggest that the MoCA may have more diverse uses with patients with various dementia than are currently being used by researchers and clinicians. It is possible that the MoCA may be useful as a measure of recall and recognition (ie, encoding and retrieval) among patients with etiologically diverse memory disorders. Given that the MoCA examines different aspects of cognitive functioning, it should be able to identify different types of memory impairment found among patients with AD and HD. This study examined this hypothesis.

The MoCA, like the MMSE, is a 30-point assessment of global function.²¹ However, the MoCA evaluates a broader array of cognitive functions (eg, executive functioning, memory, etc) without sacrificing brevity.¹⁰ From the perspective of examining recall and recognition memory, the MoCA provides a means of tracking free, category-cued, and multiple-choice recall—though this is an optional aspect of the instrument. Also, the MoCA appears to have decreased susceptibility to educational and cultural artifacts and is robust to major ceiling effects in normal control (NC) groups.^8,10 As a global assessment, Nasreddine et al proposed a cutoff of 26 versus 25 for identifying MCI.⁸ No additional cutoff was established for dementia, as the test was not originally designed to demarcate MCI from AD.⁸ Some researchers have suggested that a lower cutoff for MCI (eg, 23 vs 22) might yield greater specificity without diminishing sensitivity.^11,18 Though research has explored performance on the MoCA in AD, PD, and HD, no official cutoffs exist for these disorders as-of-yet. Nevertheless, on the whole, the MoCA appears to be a useful, brief assessment of global cognitive ability in both clinical and general populations.

Therefore, it seems that exploring the potential usefulness of particular aspects of the MoCA for the assessment of AD and HD is worthwhile as a means of enhancing cognitive assessment without increasing time demands. Given that various dementias are characterized by differing patterns of recall and encoding issues,^22

-27 it is possible that the free recall, cued recall, and recognition components of the verbal memory task on the MoCA could distinguish between types of dementia. With AD having notable encoding deficits^22,26 and HD being characterized by retrieval failures that benefit from cuing,^22,24 these 2 dementias are appropriate for this evaluation, which seeks to determine whether such nuanced aspects of memory deficits can be distinguished by assessing all levels of recall performance (ie, free recall, cued recall, and multiple-choice recognition, not just the free recall score) on the MoCA memory section. Given that AD and HD are easily distinguishable diseases, which also differ in this regard, they serve as optimal dementias upon which to perform this initial analysis to determine whether expected differences in memory processes are identifiable. This could provide benefits to researchers and clinicians alike, permitting them to perform more thorough evaluations of participants (eg, screening NCs for trials) and patients with different dementias—far beyond AD and HD. In order to assess the utility of the MoCA for evaluating recall and recognition memory, we administered the measure to a large sample comprised of healthy, community-dwelling adults, and individuals affected by HD or AD. It was hypothesized that the MoCA’s verbal recall task would be able to identify differential types of memory impairment among control, AD, and HD participants. Specifically, it was hypothesized that those affected by AD would benefit significantly less from the presentation of cuing than either those with HD or control participants.

Method

Participants

In the current, retrospective, archival study, we examined recall and recognition memory in 80 participants with well-characterized HD, 64 participants with well-characterized AD, and 183 community-dwelling, NC using the MoCA. Participants were followed at the University of California, San Diego (UCSD) Huntington Disease Center of Excellence (HD COE) and the UCSD Shiley-Marcos Alzheimer’s Disease Research Center (ADRC). The institutional review board of UCSD approved this study, and all participants provided informed consent. Participants completed the MoCA as part of a more exhaustive cognitive and medical assessment. Participants with AD were diagnosed by staff neurologists at the ADRC, and participants with HD were classified on the basis of the diagnostic confidence levels assigned by an experienced movement disorder neurologist (J.C-B.) on the Unified Huntington Disease Rating Scale.²⁷ Controls consisted mainly of spouses and friends of patients seen through the UCSD HD COE and ADRC. The remaining participants were recruited from the San Diego community as part of a convenience sample. Any prospective control participants with MMSE scores lower than 27 were excluded from the analyses. For demographic information and average MMSE and MoCA scores, see Table 1.

Table 1.

Demographic and Clinical Characteristics of HD, AD, and NC Groups.

	HD	AD	NC	P	R ²
Age (years)	52.49 (14.15)^a	77.24 (8.07)^a	62.10 (16.50)^a	<.001	0.2374
Education (years)	14.15 (3.07)^a	15.79 (2.99)	15.34 (2.40)	<.001	0.0454
MMSE score	23.51 (4.74)	23.20 (4.56)	28.66 (1.34)^a	<.001	0.3997
MoCA score	18.88 (5.89)	18.05 (5.61)	27.91 (1.98)^a	<.001	0.5693

Abbreviations: AD, Alzheimer disease; HD, Huntington disease; NC, community-dwelling normal control; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment.

^aGroup identified as statistically significantly different from other 2 using Tukey honest significant difference (P ≤ .004).

Procedures

Participants were given the original English version of the MoCA. During this test, a list of 5 words (FACE, VELVET, CHURCH, DAISY, RED) was read to the participants twice. After each reading, participants were asked to repeat the words back to the examiner. After the second iteration, participants were told to remember this list of words for a later portion of the test.²⁸ After a 5-minute delay, during which other cognitive tasks are performed, participants were asked to recall as many of the 5 words as they could, in any order. If there was a word a participant was unable to recall, they were provided with a category cue (eg, “the word you are trying to remember was a color” [for RED]). Finally, if a participant was unable to recollect the word following this prompt, they were given 3 category appropriate options (eg, “was it RED, was it BLUE, or was it GREEN” [for RED]) and asked to identify which word was the one that was on the list. The progression of this assessment lent itself to the use of binary logistic regression models, which were used to analyze the probability of success or failure on each task (ie, free recall, cued recall, recognition) as a function of diagnostic status.

Analyses

Maximum-likelihood models were used to examine differences across HD, AD, and NC groups, because of the binary nature of the outcome (ie, correct/incorrect). The analysis was a random-effects binary logistic regression panel model where words were nested within participants. Ability to recall or recognize each word was assessed sequentially. Thus, the word “RED” at “free recall” could have been answered correctly or incorrectly. If incorrectly, it was entered into the next analysis “category cued recall,” where it could be answered correctly or incorrectly. Finally, if still incorrect, it was analyzed at “multiple-choice recognition” where it could be answered correctly or incorrectly. Specifically, analyses were performed to determine whether HD, AD, and NC groups differed in their probabilities of succeeding at identifying the correct word at free recall, category cued recall, and multiple-choice recognition levels. For each analysis, age and education were entered as covariates as a means of controlling for differences due to these factors.

Results

The first analysis examined free recall outcomes (N = 1570; i = 314). The model was significant, χ²(2) = 132.17, P < .001; age, Wald z(1) = −4.17, P < .001, b = −0.041, but not education, Wald z(1) = 1.57, P = .116, b = 0.082, significantly impacted free recall outcomes. Diagnostic status significantly impacted free recall outcomes as well, χ²(2) = 119.89, P < .001. Contrast 1 (AD vs NC), χ²(1) = 77.52, P < .001, b = −3.908, odds ratio (OR) = 0.02, and contrast 2 (HD vs NC), χ²(1) = 69.89, P < .001, b = −2.996, OR = 0.05, were statistically significant. This demonstrates that NC participants had a significantly higher probability of recalling the correct word at the free recall level compared to participants with both AD and HD. However, at the free recall level, contrast 3 (AD vs HD) yielded no significant difference, χ²(1) = 3.30, P = .0694, b = 0.912, OR = 2.489. Thus, participants with AD and HD did not differ significantly from one another in their ability to recall freely the target words.

The second analysis assessed category cued outcomes (N = 776, i = 242). This model was also statistically significant, χ²(4) = 26.96, P < .001. At the category cued level, performance was not significantly predicted by age, Wald z(1) = 1.05, P = .293, b = 0.008, or education, Wald z(1) = 0.64, P = .523, b = 0.023. The effect of diagnostic status was statistically significant, χ²(2) = 26.26, P < .001. Simple contrasts demonstrated that there was a significant difference between the AD and NC groups at the category cued level of recall, χ²(1) = 26.15, P < .001, b = −1.385, OR = 0.250, but there was no statistically significant difference between the HD and NC groups, χ²(1) = 0.077, P = .38, b = −0.227, OR = 0.797. Thus, when cued, NC and participants with HD who had failed to recall freely 1 of the 5 words had statically equivalent probabilities of remembering the correct word, but statistically participants with AD gained no benefit from cuing and remained significantly less likely to recall the correct word compared to NC participants. There was also a statistically significant difference between the participants with HD and AD at this level, χ² (1) = 12.44, P < .001, b = 1.158, OR = 3.184, such that participants with HD who had not recalled a word freely performed significantly better at the cued level of recall than participants with AD who had not recalled a word freely.

The third analysis examined multiple-choice recognition outcomes (N = 543, i = 204). The model was statistically significant, χ²(4) = 33.53, P < .001. Neither age, Wald z(1) = 0.50, P = .616, b = 0.006, nor education, Wald z(1) = 0.75, P = .454, b = 0.042, significantly impacted the probability of correctly recognizing a word at the multiple-choice level. The effect of diagnostic status was statistically significant, χ²(2) = 31.14, P < .001. Simple contrasts demonstrated that there was still no relative benefit conferred to participants with AD in the recognition task, as participants with AD continued to perform significantly worse than NC participants, χ²(1) = 31.12, P < .001, b = −2.476, OR = 0.084. However, in the recognition task, participants with HD again differed significantly from NC participants, χ²(1) = 4.21, P = .04, b = −0.910, OR = 0.402. Thus, participants with HD who were unable to recall the correct word at the free and cued recall levels were significantly less likely to be able to recognize it than comparable NC participants (for overall relative frequencies of free recall, cued recall, recognition, and incorrect responses for NC, AD, and HD groups, see Figure 1). The contrast comparing participants with HD and AD demonstrated that, again, there was a statistically significant difference between these group, χ²(1) = 9.47, P = .002, b = 1.565, OR = 4.784. Thus, participants with HD who were unable to recall a word after receiving a category cue were significantly more likely to recognize the word than participants with AD in the same condition.

Figure 1.

Relative frequencies of free recall, cued recall, multiple-choice recognition, and incorrect responses for normal control, participants with AD, and participants with HD. AD indicates Alzheimer disease; HD, Huntington disease; NC, normal control.

Discussion

In the current study, we examined the utility of the MoCA as a means of identifying specific memory functions (ie, recall and recognition) in AD and HD. To our knowledge, this is the first study to investigate this directly. We found that the MoCA was capable not only of differentiating NC from participants with AD and HD at each level of memory performance (ie, free recall, cued recall, and multiple-choice recognition) but also of differentiating participants with AD and HD.

Our examination of recall and recognition memory differences between participants with HD, participants with AD, and NC provides valuable insight into the prospective utility of the MoCA as a brief, clinical assessment to analyze memory profiles in dementia. It suggests that the MoCA, already recognized as a useful cognitive measure, has utility beyond that which is often exploited currently by researchers and clinicians. Clearly, examining specific aspects of recall and recognition in HD and AD populations provides detail that may be lost in analyses that simply average across these levels (eg, using the total score for memory on the MoCA).

The patterns of differentiation among HD, AD, and NC samples based upon free recall, cued recall, and multiple-choice recognition are consistent with previously reported findings using other measures of memory.^22

-25 First, the analyses demonstrate what would be expected for the differences between NC and participants with AD; specifically, that no statistically significant benefits were conferred via any form of cuing for the participants with AD. This would be anticipated, as AD is a disorder associated with encoding deficits, especially as the disorder progresses, but which may be present early in the disease course as well.^26,29 Given that other evidence has suggested that consolidation deficits may be the early indicators of AD, with encoding failure manifesting later in the disease course,³⁰ future research would benefit from examining clinical populations with this form of analysis controlling for disease duration or severity.

At the free recall level, perhaps as would be expected, NC participants were significantly more likely to correctly recall the target word than participants with HD. However, at the cued recall level, NC and participants with HD performed statistically equivalently. Thus, among NC and participants with HD who were unable to recall freely a target word, their probability of recalling correctly after a category cue was statistically equivalent. Yet, for those of the participants with HD whose memory had been impacted severely (ie, those who could not recall the word even when cued), it seems that both retrieval and encoding deficits manifest, as even recognizing the correct word became a task with statistically significant proportions of failure compared to NC participants. This is consistent with past research that has shown that patients with HD in more advanced stages of the disease show recognition deficits comparable to patients with AD.³¹ However, we cannot conclude definitively that encoding deficits, not retrieval deficits, were the mechanisms underlying the subpar recognition performance observed in our study. These findings are consistent with past research and provide statistical, face, and clinical validity to the MoCA with respect to its ability to examine memory encoding and retrieval processes specifically.

Another finding in support of the MoCA’s usefulness was that it identified a relative increase in performance for participants with HD in the category cued recall condition. This is consistent with past research that has demonstrated that individuals with HD benefit from cuing.^22

-25 However, it is important to remember that these analyses utilized the standard progression of clinical assessment using the MoCA, meaning that only words missed at a prior level were entered into subsequent levels of the analysis (eg, only if a word was missed at the free recall level could it be assessed at the category cue level, because once a participant correctly identified a word, no subsequent promptings occurred). Thus, this finding seems to suggest that retrieval may be impaired initially in HD—that is, individuals whose memory has been impacted least by HD experience deficits in retrieval. However, when prompted adequately, this deficit can be surmounted for these individuals. A final, and perhaps most important, finding of clinical importance was the ability of this brief memory assessment on the MoCA to differentiate participants with AD and HD. As would be expected, the MoCA was able to identify the markedly degenerated memory of the participants with AD as worse than that of the participants with HD.

The greatest clinical implications of this finding appear to be that the MoCA can be used in a way that is beyond its typical scoring to provide greater detail regarding memory deficits. The fact that such a brief test can distinguish these 2 differing dementias in a way that is consistent with what is known about them is meaningful. Although this is not meant to insinuate that the MoCA would be a diagnostic tool per se, it does provide evidence for the MoCA’s ability to provide greater clinical insights than often gleaned from it presently. This is particularly true given the fact that at the free recall level (which is all that is scored on the MoCA), participants with HD and AD did not differ significantly from one another. This finding is consistent with data from Table 1, which shows that neither MoCA nor MMSE scores alone differentiated these 2 groups, but these analyses of memory subtyping were able to do so. Thus, although it may not be meaningful clinically per se to differentiate patients with HD and AD in this fashion—as there are many well-established means to do this—it is meaningful to find that specific types of memory differences can be identified by the memory portion of the MoCA beyond its present scoring of providing a point for every freely recalled word. This type of additional analysis may be useful in distinguishing other, less differentiable memory disorders (eg, vascular dementia and AD) by assessing particular memory profiles. Patients with HD and AD merely provided a worthwhile opportunity to explore this possibility among 2 distinguishable diseases to confirm that the known patterns of memory deficits were, in fact, identified by such a brief—and previously untapped—resource.

There are a few cautions that should be borne in mind when interpreting these findings. First, we used convenience, although well characterized, samples from 1 academic center. Second, the nature of the MoCA is such that the possibility of differential carryover effects poses a realistic concern. Although our use of panel data analysis helps to control for the within-person differences in recall typologies, it cannot replace methodological protections for such prospective problems (eg, randomization of participants in free recall only, cued recall only, and multiple-choice recognition only conditions for analysis). Also, it is important to bear in mind the sequential nature of our analyses; specifically, entering individuals who performed perfectly at the free recall level would have affected only the probabilities at this level, because none of these individuals would have performed the cue or recognition tasks. Thus, including these participants in the model likely only would have enhanced the already statistically significant, between-group differences at the free recall level of analysis. The average age of our participants with HD, AD, and NC were predictably different (ie, participants with HD were the youngest and participants with AD were the oldest). Yet, because age and education were entered into all analyses as covariates, the observed differences that were attributed to diagnostic status cannot be a function of age. Lastly, although it is a common practice to use a score of less than 27 on the MMSE to exclude individuals from NC groups, there has been evidence that the MMSE lacks sensitivity,³² which could have resulted in an inclusion of some individuals with unknown memory disorders in our NC sample.

Conclusion

Our research shows that the MoCA is a test with utility beyond what is acknowledged widely or considered in its scoring. It suggests that the MoCA is a rapidly administered measure capable of identifying specific memory deficits in both AD and HD. These findings hold implications for clinical practice. The MoCA offers a brief and sensitive measure to assess patients with AD and HD and differentially identify areas of memory deficit. This knowledge will provide practitioners with necessary information to tailor interventions that address the specific presentation of memory impairment. Consistent with previous research, this supports the value of the MoCA as a brief cognitive assessment for many forms of dementia. It seems that future research should further explore the full breadth of the usefulness of the MoCA, exploring correlates of differential recall on this test and considering including this aspect in its scoring.

Footnotes

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the UCSD Huntington Disease Society of America Center of Excellence and UCSD Shiley-Marcos Alzheimer Disease Research Center NIH P50 AG 005131.

References

Grahn

Parkinson

Owen

. The cognitive functions of the caudate nucleus. Prog Neurobiol. 2008;86(3):141–155.

Zadikoff

Fox

Tang-Wai

. A comparison of the Mini Mental State Exam to the Montreal Cognitive Assessment in identifying cognitive deficits in Parkinson’s disease. Mov Disord. 2008;23(2):297–299.

Pagonabarraga

Kulisevsky

. Cognitive impairment and dementia in Parkinson’s disease. Neurobiol Dis. 2012;46(3):590–596.

Dumas

van den Bogaard

Middelkoop

Roos

. A review of cognition in Huntington’s disease. Front Biosci (Schol Ed). 2013;5:16–43.

El Haj

Caillaud

Fasotti

Verny

Allain

. Episodic memory decline in Huntington’s disease, a binding deficit? J Huntingtons Dis. 2013;2(3):305–313.

Lemiere

Decruyenaere

Evers-Kiebooms

Vandenbussche

Dom

. Cognitive changes in patients with Huntington’s disease (HD) and asymptomatic carriers of the HD mutation. J Neurol. 2004;251(8):935–942.

Snowden

Craufurd

Griffiths

Thompson

Neary

. Longitudinal evaluation of cognitive disorder in Huntington’s disease. J Int Neuropsychol Soc. 2001;7(1):33–44.

Nasreddine

Phillips

Bedirian

. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699.

Gill

Freshman

Blender

Ravina

. The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson’s disease. Mov Disord. 2008;23(7):1043–1046.

10.

Ismail

Rajji

Shulman

. Brief cognitive screening instruments: an update. Int J Geriatr Psychiatry. 2010;25(2):111–120.

11.

Luis

Keegan

Mullan

. Cross validation of the Montreal Cognitive Assessment in community dwelling older adults residing in the southeastern US. Int J Geriatr Psychiatry. 2009;24(2):197–201.

12.

Mickes

Jacobson

Peavy

. A comparison of two brief screening measures of cognitive impairment in Huntington’s disease. Mov Disord. 2010;25(13):2229–2233.

13.

Videnovic

Bernard

Fan

Jaglin

Leurgans

Shannon

. The Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in Huntington’s disease. Mov Disord. 2010;25(3):402–404.

14.

Roalf

Moberg

Xie

Wolk

Moelter

Arnold

. Comparative accuracies of two common screening instruments for classification of Alzheimer’s disease, mild cognitive impairment, and healthy aging. Alzheimers Dement. 2013;9(5):529–537.

15.

Brown

Bernstein

McClintock

. Use of the Montreal Cognitive Assessment and Alzheimer’s Disease-8 as cognitive screening measures in Parkinson’s disease. Int J Geriatr Psychiatry. 2016;31(3):264–272.

16.

Bezdicek

Majerova

Novak

Nikolai

Ruzicka

Roth

. Validity of the Montreal Cognitive Assessment in the detection of cognitive dysfunction in Huntington’s disease. Appl Neuropsychol. 2013;20(1):33–40.

17.

Gluhm

Goldstein

Brown

Van Liew

Gilbert

Corey-Bloom

. Usefulness of the Montreal Cognitive Assessment (MoCA) in Huntington’s disease. Mov Disord. 2013;28(12):1744–1747.

18.

Cecato

Martinelli

Izbicki

Yassuda

Aprahamian

. A subtest analysis of the Montreal cognitive assessment (MoCA): which subtests can best discriminate between healthy controls, mild cognitive impairment and Alzheimer’s disease? Int Psychogeriatr. 2016;28(5)825–832.

19.

Costa

Reich

Fimm

Ketteler

Schulz

Reetz

. Evidence of the sensitivity of the MoCA alternate forms in monitoring cognitive change in early Alzheimer’s disease. Dement Geriatr Cogn Disord. 2013;37(1-2):95–103.

20.

Julayanont

Phillips

Chertkow

Nasreddine

. Montreal Cognitive Assessment (MoCA): concept and clinical review. In: Larner

, ed. Cognitive Screening Instruments. London, UK: Springer; 2013:111–151.

21.

Folstein

McHugh

. Mini-Mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198.

22.

Granholm

Butters

. Associative encoding and retrieval in Alzheimer’s and Huntington’s disease. Brain Cogn. 1998;7(3):335–347.

23.

Heindel

Salmon

Butters

. Pictorial priming and cued recall in Alzheimer’s and Huntington’s disease. Brain Cogn. 1990;13(2):282–295.

24.

Massman

Delis

Butters

Levin

Salmon

. Are all subcortical dementias alike?: verbal learning and memory in Parkinson’s and Huntington’s disease patients. J Clin Exp Neuropsychol. 1990;12(5):729–744.

25.

Pillon

Deweer

Agid

Dubois

. Explicit memory in Alzheimer’s, Huntington’s, and Parkinson’s diseases. Arch Neurol. 1993;50(4):374–379.

26.

White

Ruske

. Memory deficits in Alzheimer’s disease: the encoding hypothesis and cholinergic function. Psychon B Rev. 2002;9(3):426–437.

27.

Huntington Study Group. Unified Huntington’s Disease Rating Scale: reliability and consistency. Mov Disord. 1996;11(2):136–142.

28.

Nasreddine

. The Montreal Cognitive Assessment instructions [English original]. 2010. Web site. http://www.mocatest.org/default.asp. Accessed September 14, 2016.

29.

Browndyke

Giovanello

Petrella

. Phenotypic regional functional imaging patterns during memory encoding in mild cognitive impairment and Alzheimer’s disease. Alzheimers Dement. 2013;9(3):284–294.

30.

Wintraub

Wicklund

Salmon

. The neuropsychological profile of Alzheimer disease. Cold Spring Harb Perspect Med. 2012:2(4):a006171.

31.

Kramer

Delis

Blusewicz

Brandt

Ober

Strauss

. Verbal memory errors in Alzheimer’s and Huntington’s dementias. Dev Neuropsychol. 1988;4(1):1–15.

32.

Lacy

Kaemmerer

Czipri

. Standardized Mini-Mental State Examination scores and verbal memory performance at a memory center: implications for cognitive screening. Am J Alzheimers Dis Other Demen. 2015;30(2):145–152.

Evaluating Recall and Recognition Memory Using the Montreal Cognitive Assessment

Abstract

Keywords

Method

Participants

Procedures

Analyses

Results

Discussion

Conclusion

Footnotes

Declaration of Conflicting Interests

Funding

References